Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)
9,480.00
0.00 (0.00%)
At close: Feb 6, 2026
Hyundai Bioscience Revenue
Hyundai Bioscience had revenue of 553.06M KRW in the quarter ending September 30, 2025, with 20.56% growth. This brings the company's revenue in the last twelve months to 1.96B, down -87.61% year-over-year. In the year 2024, Hyundai Bioscience had annual revenue of 15.05B with 58.73% growth.
Revenue (ttm)
1.96B
Revenue Growth
-87.61%
P/S Ratio
464.43
Revenue / Employee
28.41M
Employees
69
Market Cap
910.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15.05B | 5.57B | 58.73% |
| Dec 31, 2023 | 9.48B | 1.63B | 20.76% |
| Dec 31, 2022 | 7.85B | -1.39B | -15.04% |
| Dec 31, 2021 | 9.24B | -3.27B | -26.14% |
| Dec 31, 2020 | 12.51B | -17.57B | -58.41% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.56T |
| Celltrion | 3.90T |
| Daewoong | 2.06T |
| SD Biosensor | 696.13B |
| Medy-Tox | 241.80B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| MEDIPOST | 73.59B |